2. Signalwege
  3. Immunology/Inflammation
  4. COX
  5. COX-1 Isoform

COX-1

COX-1 (cyclooxygenase-1, PTGS1) is a constitutively expressed prostaglandin-endoperoxide synthase that catalyzes the conversion of arachidonic acid into prostaglandin intermediates, thereby initiating prostaglandin and thromboxane biosynthesis essential for physiological homeostasis[1][2]. Mechanistically, COX-1 participates in the cyclooxygenase and peroxidase reactions that generate prostaglandin H2, a central precursor for multiple bioactive prostanoids regulating vascular function, platelet activity, renal perfusion, and gastrointestinal integrity[1][3]. Through sustained prostanoid production, COX-1 contributes to tissue-protective and housekeeping functions across mammalian organs, including maintenance of gastric mucosal defense and thromboxane A2-dependent platelet aggregation[3][4]. In disease and pharmacological models, inhibition of COX-1 reduces prostaglandin synthesis and underlies the therapeutic actions of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), while also contributing to gastrointestinal adverse effects associated with nonselective COX blockade[1][4][5]. Compared with the inducible isoform COX-2, which is preferentially upregulated by inflammatory stimuli and cellular stress, COX-1 exhibits stable basal expression and is primarily associated with physiological regulation rather than acute inflammatory responses[3][4][5]. For experimental applications, selective and nonselective COX inhibitors remain important tools for dissecting prostanoid-dependent signaling pathways and distinguishing constitutive versus inducible cyclooxygenase functions in inflammation, thrombosis, and tissue homeostasis[1][3][5].

COX-1 Verwandte Produkte (190):

Art. -Nr. Produktname Wirkung Reinheit
  • HY-78131A
    (S)-(+)-Ibuprofen
    		Inhibitor 99.98%
    (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
  • HY-59105
    SC-560
    		Inhibitor 99.79%
    SC-560 is a potent and selective COX-1 inhibitor with an IC50 of 9 nM.
  • HY-N0147
    Rutaecarpine
    		Inhibitor 99.09%
    Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC50 value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).
  • HY-15762
    Valdecoxib
    		Inhibitor 99.89%
    Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
  • HY-10582
    Flurbiprofen
    		Inhibitor 99.95%
    Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer.
  • HY-78131C
    Ibuprofen sodium
    		Inhibitor 99.98%
    Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.
  • HY-B0253
    Piroxicam
    		Inhibitor 99.78%
    Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
  • HY-B0808
    Oxaprozin
    		Inhibitor 99.94%
    Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties.
  • HY-15030A
    Naproxen sodium
    		Inhibitor 99.74%
    Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
  • HY-15321
    Etoricoxib
    		Inhibitor 99.86%
    Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor. Etoricoxib can cross the blood-brain barrier, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
  • HY-N8469
    cis-5-Dodecenoic acid
    		Inhibitor 99.76%
    cis-5-Dodecenoic acid is an inhibitor of COX-I and COX-II with anti-inflammatory activity. cis-5-Dodecenoic acid reduces prostaglandin synthesis by inhibiting COX enzyme activity and is involved in the fatty acid -β oxidative metabolic pathway. The metabolic rate of cis-5-Dodecenoic acid is significantly lower than that of saturated fatty acids. cis-5-Dodecenoic acid can be used in the research of anti-inflammation, fatty acid metabolism mechanisms and related physiological and pathological processes.
  • HY-N0481
    Roburic acid
    		Inhibitor 99.93%
    Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a Ki of 7.066 μM against human TNF, an IC50 of 9 μM against human COX-2, and an IC50 of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.
  • HY-76251
    Etodolac
    		Inhibitor 99.48%
    Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that can cross the blood-brain barrier and is a non-selective inhibitor of COX (IC50=53.5 nM)
  • HY-N0396
    Harpagoside
    		Inhibitor 99.88%
    Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).
  • HY-B0580
    Ketorolac
    		Inhibitor 99.87%
    Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research.
  • HY-66005R
    Acetaminophen (Standard)
    		Inhibitor
    Acetaminophen (Standard) is the analytical standard of Acetaminophen. This product is intended for research and analytical applications. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
  • HY-13507
    Lumiracoxib
    		Inhibitor 99.93%
    Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM. Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.
  • HY-B1153
    Glafenine
    		Inhibitor 98.77%
    Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF).
  • HY-B2137
    S-(+)-Ketoprofen
    		Inhibitor 99.88%
    S-(+)-Ketoprofen is a potent inhibitor of both COX-1 and COX-2 with IC50s of 1.9 and 27 nM, respectively.
  • HY-126052
    Gnetol
    		Inhibitor 99.86%
    Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities.